Squamous cell carcinoma

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

Retrieved on: 
Thursday, November 10, 2022

These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.

Key Points: 
  • These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.
  • We are excited to continue advancing DRAGON and look forward to sharing additional data next year.
  • The biomarker strategy for DRAGON explores early signs of SRK-181 activity, including target engagement and pathway modulation.
  • The DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in patients with locally advanced or metastatic solid tumors is ongoing.

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022

SAN FRANCISCO, Nov. 10, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • NKTR-288 is a novel polyethylene glycol (PEG)-conjugate of interferon gamma (IFN-), designed to modify binding of IFN- to its substrates and optimize the duration of IFN- signaling.
  • These data support further evaluation of NKTR-288 as a monotherapy or in combination with checkpoint inhibitors in the clinical setting.
  • It highlights the potential of NKTR-288 to augment currently available PD-1 or PD-L1 treatment strategies and possibly broaden the responsive patient population."
  • Key details and takeaways from the presentation are as follows:
    Abstract 1086: "NKTR-288, a PEGylated Interferon Gamma Drug Candidate for the Treatment of Cancer", Hamel, D., et al.

Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, November 8, 2022

WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2022, and recent corporate highlights.

Key Points: 
  • WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2022, and recent corporate highlights.
  • In July 2022, Checkpoint successfully completed two pre-BLA meetings with the FDA (chemistry, manufacturing and controls [CMC] and clinical/non-clinical).
  • Checkpoint expects its common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market in December 2022.
  • Research and development expenses for the third quarter of 2022 included $0.3 million of non-cash stock expenses, compared to $0.2 million for the third quarter of 2021.

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Retrieved on: 
Tuesday, November 8, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights.
  • Patient enrollment for ASPEN-03 and ASPEN-04 continues as planned with results expected to be presented by the middle of 2024.
  • Third Quarter 2022 Financial Results:
    Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments were $293.1 million as of September 30, 2022.
  • ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

Retrieved on: 
Tuesday, November 8, 2022

Ended quarter with $218 million in cash, cash equivalents and short-term investments

Key Points: 
  • Ended quarter with $218 million in cash, cash equivalents and short-term investments
    LEXINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancers and infectious disease, today provided a corporate update and reported financial results for the third quarter of 2022.
  • Cash used in operations was $32.2 million for the quarter ended September 30, 2022, and $128 million for the nine-months then ended.
  • We recognized revenue of $22.8 million and incurred a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022.
  • Non-cash operating expenses for the third quarter and nine-months ended September 30, 2022, were $22.2 million and $62.8 million respectively.

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022

WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.

Key Points: 
  • WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.
  • Research and development expenses were $2.9million in the third quarter of 2022, compared to $3.8 million for the same period in 2021.
  • General and administrative expenses were $3.9million in the third quarter of 2022, compared to $8.0 million for the same period in 2021.
  • As of September 30, 2022, Verrica had aggregate cash, cash equivalents, marketable securities and restricted cash of $39.5million.

Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update

Retrieved on: 
Tuesday, November 8, 2022

Dosing our first patient in the Phase II expansion portion of the BT8009 trial is a key development milestone for Bicycle, said Kevin Lee, Ph.D., Chief Executive Officer.

Key Points: 
  • Dosing our first patient in the Phase II expansion portion of the BT8009 trial is a key development milestone for Bicycle, said Kevin Lee, Ph.D., Chief Executive Officer.
  • Two doses have been selected as the recommended Phase II doses (RP2Ds): 5mg/m2 weekly and 7.5mg/m2 2-weeks on, 1-week off (over a 21-day cycle).
  • The Phase II multi-center, open label trial will evaluate BT8009 administered at the RP2Ds of 5mg/m2 and 7.5mg/m2.
  • The ongoing dose expansion includes cohorts evaluating the activity of BT8009 in CPI combination cohorts as well as in cohorts of patients with renal impairment.

TOOsonix announces granted patents for its non-invasive treatments of dermatological conditions

Retrieved on: 
Wednesday, November 9, 2022

HOERSHOLM, Denmark, Nov. 9, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) technology for dermatology, today announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent no. 11/491,351 regarding its key technologies. The U.S. patent and already granted patents in Europe and China therefore complete the first phase of securing intellectual property rights for TOOsonix's unique technology in the major jurisdictions.

Key Points: 
  • The patents define methods for non-invasive and real-time image-guided treatment of skin using therapeutic ultrasound.
  • The technology has been implemented in the company's first product TOOsonix System ONE-M, which is currently in the late phase of approvals for medical treatments.
  • Torsten Bove and Tomasz Zawada, Co-founders of TOOsonix state: "Having patents in our three main markets has always been an essential milestone for the company.
  • TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its unique and patented high-frequency focused ultrasound device.

TOOsonix announces granted patents for its non-invasive treatments of dermatological conditions

Retrieved on: 
Wednesday, November 9, 2022

HOERSHOLM, Denmark, Nov. 9, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) technology for dermatology, today announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent no. 11/491,351 regarding its key technologies. The U.S. patent and already granted patents in Europe and China therefore complete the first phase of securing intellectual property rights for TOOsonix's unique technology in the major jurisdictions.

Key Points: 
  • The patents define methods for non-invasive and real-time image-guided treatment of skin using therapeutic ultrasound.
  • The technology has been implemented in the company's first product TOOsonix System ONE-M, which is currently in the late phase of approvals for medical treatments.
  • Torsten Bove and Tomasz Zawada, Co-founders of TOOsonix state: "Having patents in our three main markets has always been an essential milestone for the company.
  • TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its unique and patented high-frequency focused ultrasound device.

Cardiff Oncology to Present at the Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022

A replay of the presentation will be available by visiting the " Events " section of the Cardiff Oncology website and will be archived for 90 days.

Key Points: 
  • A replay of the presentation will be available by visiting the " Events " section of the Cardiff Oncology website and will be archived for 90 days.
  • Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.
  • These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone.
  • For more information, please visit https://www.cardiffoncology.com .